

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc | Company Release | May 21, 2024 at 17:00:00 EEST

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc ("BBS") has received 21 May 2024 requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 50,000 of the convertible notes into Company shares at a conversion price of EUR 0.32247 per share. The conversion shall be executed by transferring a total of 155,053 treasury shares to Riverfort.

The Conversion price according to the terms and conditions is "90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice".

After the transfers, the Company will hold a total of 216,647 treasury shares in its possession.

For more information, please contact:

Juliusz Rakowski, CEO

+358 50 448 5132

juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB,

+46 70 551 67 29,

info@certifiedadviser.se

Distribution

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>



Company Release
21 May 2024 17:00:00 EEST

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi